Evidence map›Paper›PMID 40610401›Full record

ArticleBlood cancer journal2025

Incidental vs. symptomatic diagnosis of follicular lymphoma: implications of earlier detection.

Suheil Albert Atallah-Yunes, Matthew J Rees, Raphael Mwangi, Robyn L Kuchler, Ahmed Alnughmush, Grzegorz S Nowakowski, Thomas M Habermann, Yucai Wang, Jose C Villasboas Bisneto, Andrew L Feldman and 4 more

Abstract read
In one paragraph

Article in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Suheil Albert Atallah-YunesDivision of Hematology, Mayo Clinic, Rochester, MN, USA. albert.atallahmd@gmail.com.ORCID 0000-0003-3380-5326
Matthew J ReesDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-8360-2952
Raphael MwangiDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Robyn L KuchlerAlix School of Medicine, Mayo Clinic, Rochester, MN, USA.
Ahmed AlnughmushDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Grzegorz S NowakowskiDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-6955-9393
Thomas M HabermannDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-3532-9132
Yucai WangDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-1576-8341
Jose C Villasboas BisnetoDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-2907-0809
Andrew L FeldmanDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-5009-4808
Matthew J MaurerDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-1867-0526
James R CerhanDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-7482-178X
Stephen M AnsellDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-1244-6758
Thomas E WitzigDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-4215-6500

Funding

The Role of Monocytes in non-Hodgkin LymphomaP50CA097274 · NCI · UNIVERSITY OF IOWA · PI LENTZ, STEVEN R · 2002 to 2021
$45.7M
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study (Supplement)U01CA195568 · NCI · MAYO CLINIC ROCHESTER · PI CERHAN, JAMES R, FLOWERS, CHRISTOPHER R · 2015 to 2025
$22.1M
NCI NIH HHS P50 CA097274NCI NIH HHS U01 CA195568
6 · The paper itself

Abstract

Follicular lymphoma (FL) is usually diagnosed at an advanced stage when the patient presents with a palpable lymph node or symptoms such as pain and fatigue. However, due to advances in imaging techniques used for many diseases and cancer screening, incidental diagnosis of FL is expected to rise. In this study, we investigated FL disease characteristics and outcomes in patients diagnosed incidentally versus symptomatically, providing insights into what might be detected with multi-cancer early detection tests (MCEDs). We conducted a review of 908 patients with newly diagnosed FL enrolled in the Mayo Clinic component of the Molecular Epidemiology Resource (MER) from 2002 to 2015. We compared disease characteristics and outcomes between the incidental and symptomatic groups. Of the 908 patients, 259 (28.5%) were diagnosed incidentally. The incidental group was more likely to present with early-stage disease (stage I/II: 43.2% vs. 30.6%, p = 0.0003), normal lactate dehydrogenase (LDH) levels (87.2% vs. 80.8%, p = 0.03), and trended towards having lower FLIPI scores (49.8% vs. 42.2%, p = 0.1). However, there were no significant differences in event-free survival (EFS), overall survival (OS) or lymphoma-specific survival (LSS) between the two groups. In conclusion, incidental detection of FL is associated with earlier stages and more favorable disease characteristics. However, this did not translate into improved survival outcomes. Whether even earlier detection of FL using emerging MCEDs translates into improved outcomes remains an open question requiring further investigation.

Indexed as

Early Detection of CancerIncidental FindingsLymphoma, FollicularAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosis

Identifiers

PMID40610401
PMCPMC12229598

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.